- Home
- ABTS vs MBIO Comparison
ABTS vs MBIO Comparison
Compare ABTS & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.00
HOLD
Current Price
$0.75
Company Overview
Basic Information| Metric | ABTS | MBIO |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 6.2M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ABTS | MBIO |
|---|---|---|
| Price | $2.00 | $0.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 20.8K | ★ 29.6K |
| Earning Date | 04-30-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $0.53 |
| 52 Week High | $10.86 | $7.00 |
Technical Indicators
Market Signals| Indicator | ABTS | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 32.15 | 29.24 |
| Support Level | N/A | $0.53 |
| Resistance Level | $3.00 | $1.00 |
| Average True Range (ATR) | 0.23 | 0.07 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 4.90 | 3.16 |
Price Performance
Historical Comparison ABTS
MBIO
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations. The group has its subsidiaries in USA, China, Canada and Hong Kong.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.